Compare BCDA & ZDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCDA | ZDAI |
|---|---|---|
| Founded | N/A | 2022 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | General Bldg Contractors - Nonresidential Bldgs |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.4M | 14.8M |
| IPO Year | N/A | 2024 |
| Metric | BCDA | ZDAI |
|---|---|---|
| Price | $1.42 | $0.36 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $25.00 | N/A |
| AVG Volume (30 Days) | 64.9K | ★ 2.3M |
| Earning Date | 11-12-2025 | 12-16-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $19,275,673.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 43.16 |
| 52 Week Low | $1.00 | $0.34 |
| 52 Week High | $3.20 | $2.25 |
| Indicator | BCDA | ZDAI |
|---|---|---|
| Relative Strength Index (RSI) | 54.40 | 36.54 |
| Support Level | $1.32 | $0.34 |
| Resistance Level | $1.34 | $0.39 |
| Average True Range (ATR) | 0.07 | 0.03 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 84.00 | 25.76 |
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
DirectBooking Technology Co Ltd, formerly Primega Group Holdings Ltd is engaged in transportation services. It operates in the Hong Kong construction industry, mainly handling the transportation of materials excavated from construction sites. Its services principally comprise (i) soil and rock transportation services; (ii) diesel oil trading; and (iii) construction works, which mainly include ELS works and bored piling. The company provide services as a subcontractor to other construction contractors in Hong Kong. Maximum revenue is generated from soil and rock transportation services.